Neutralization of lenvatinib charge hampers encapsulation into ferritin nanocages

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11310%2F19%3A10422997" target="_blank" >RIV/00216208:11310/19:10422997 - isvavai.cz</a>
Alternative codes found
RIV/62156489:43210/19:43917156 RIV/00216208:11320/19:10422997
Result on the web
<a href="https://mendelnet.cz/artkey/mnt-201901-0128_Neutralization-of-lenvatinib-charge-hampers-encapsulation-into-ferritin-nanocages.php?back=/magno/mnt/2019/mn1.php?secid=4" target="_blank" >https://mendelnet.cz/artkey/mnt-201901-0128_Neutralization-of-lenvatinib-charge-hampers-encapsulation-into-ferritin-nanocages.php?back=/magno/mnt/2019/mn1.php?secid=4</a>
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Neutralization of lenvatinib charge hampers encapsulation into ferritin nanocages
Original language description
Lenvatinib is an oral multi-target tyrosine-kinase (TK) inhibitor. Ferritins are proteins naturally occurring in human body, where they are responsible for the iron storage, transport and harmful ferrous species detoxification. The ferric-ions-free apo-form of ferritins can be used for drug encapsulation and delivery to tumor cells. To avoid harmful side effects and increase the anticancer efficiency, we investigated to prepare lenvatinib-loaded apoferritin (ApoLen) nanoparticles. We tested various experimental conditions, i.e. different lenvatinib solvents and pH. Nevertheless, the construction of ApoLen nanoparticles was not successful. Therefore, lenvatinib interactions with the apoferritin cavity as well as lenvatinib encapsulation into the ApoLen nanoparticles were studied in silico using molecular dynamics (MD) simulations. In accordance with experimental results, theoretical models demonstrated that lenvatinib molecules are not suitable for preparation of ApoLen nanoparticles.
Czech name
—
Czech description
—

Project
<a href="/en/project/GA18-10251S" target="_blank" >GA18-10251S: Comprehensive insight into mechanisms of action and metabolism of tyrosine kinase inhibitors and a study of ways increasing their antitumor efficiency</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Article name in the collection
MENDELNET 2019: Proceedings of 26th International PhD Students Conference
ISBN
978-80-7509-688-3
ISSN
—
e-ISSN
—
Number of pages
6
Pages from-to
665-670
Publisher name
Vydavatelství Mendelovy univerzity v Brně
Place of publication
Brno
Event location
Agronomická fakulta, Mendelova Univerzita v Brně
Event date
Nov 6, 2019
Type of event by nationality
EUR - Evropská akce
UT code for WoS article
000576735500120

Similar results(10)